File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Platelet-rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein-2

TitlePlatelet-rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein-2
Authors
KeywordsBone Graft
Bone Morphogenetic Proteins
Bone Regeneration
Delivery System
Fibrin
Growth Substances
Platelet-Rich Plasma (Prp)
Issue Date2005
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLR
Citation
Clinical Oral Implants Research, 2005, v. 16 n. 6, p. 676-682 How to Cite?
AbstractThe aim of the present study was (1) to test whether or not platelet-rich plasma (PRP) or commercially available fibrin can increase bone regeneration compared with non-treated defects and (2) to test whether or not PRP or fibrin increases bone regeneration when used as a delivery system for recombinant human bone morphogenetic protein-2 (rhBMP-2). In 16 New Zealand White rabbits, four evenly distributed 6 mm diameter defects were drilled into the calvarial bone. The following five treatment modalities were randomly allocated to all 64 defects: (0) untreated control, (1) fibrin alone, (2) PRP alone, (3) fibrin with 15 μg rhBMP-2 and (4) PRP with 15 μg rhBMP-2. For the fibrin gels and the PRP containing rhBMP-2, the 15 μg rhBMP-2 was incorporated by precipitation within the matrices before their gelation. After 4 weeks, the animals were sacrificed and the calvarial bones were removed for histological preparation. The area fraction of newly formed bone was determined in vertical sections from the middle of the defect by applying histomorphometrical analysis. A mean area fraction of newly formed bone was found within the former defect of 23.4% (±13.5%) in the control sites, of 28.4% (±17.4%) in the fibrin sites and of 34.5% (±17.4%) in the PRP sites. The statistical analysis revealed no significant difference in bone formation between the three groups (ANOVA). Addition of 15 μg rhBMP-2 in the fibrin gel (59.9±20.3%) and the PRP gels (63.1±25.3%) increased bone formation significantly. No significant difference was observed between sites, where PRP or fibrin has been used as a delivery system for rhBMP-2 (ANOVA). In conclusion, the application of fibrin gels or PRP gels to bone defects is not superior to leaving the defect untreated. Regarding the amount of bone formation, the application of 15 μg rhBMP-2 in bone defects enhances the healing significantly at 4 weeks. In this animal model, commercially available fibrin and autologous PRP gels are equally effective as delivery systems for rhBMP-2. Copyright © Blackwell Munksgaard 2005.
Persistent Identifierhttp://hdl.handle.net/10722/154386
ISSN
2015 Impact Factor: 3.464
2015 SCImago Journal Rankings: 1.427
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorJung, REen_US
dc.contributor.authorSchmoekel, HGen_US
dc.contributor.authorZwahlen, Ren_US
dc.contributor.authorKokovic, Ven_US
dc.contributor.authorHammerle, CHFen_US
dc.contributor.authorWeber, FEen_US
dc.date.accessioned2012-08-08T08:25:01Z-
dc.date.available2012-08-08T08:25:01Z-
dc.date.issued2005en_US
dc.identifier.citationClinical Oral Implants Research, 2005, v. 16 n. 6, p. 676-682en_US
dc.identifier.issn0905-7161en_US
dc.identifier.urihttp://hdl.handle.net/10722/154386-
dc.description.abstractThe aim of the present study was (1) to test whether or not platelet-rich plasma (PRP) or commercially available fibrin can increase bone regeneration compared with non-treated defects and (2) to test whether or not PRP or fibrin increases bone regeneration when used as a delivery system for recombinant human bone morphogenetic protein-2 (rhBMP-2). In 16 New Zealand White rabbits, four evenly distributed 6 mm diameter defects were drilled into the calvarial bone. The following five treatment modalities were randomly allocated to all 64 defects: (0) untreated control, (1) fibrin alone, (2) PRP alone, (3) fibrin with 15 μg rhBMP-2 and (4) PRP with 15 μg rhBMP-2. For the fibrin gels and the PRP containing rhBMP-2, the 15 μg rhBMP-2 was incorporated by precipitation within the matrices before their gelation. After 4 weeks, the animals were sacrificed and the calvarial bones were removed for histological preparation. The area fraction of newly formed bone was determined in vertical sections from the middle of the defect by applying histomorphometrical analysis. A mean area fraction of newly formed bone was found within the former defect of 23.4% (±13.5%) in the control sites, of 28.4% (±17.4%) in the fibrin sites and of 34.5% (±17.4%) in the PRP sites. The statistical analysis revealed no significant difference in bone formation between the three groups (ANOVA). Addition of 15 μg rhBMP-2 in the fibrin gel (59.9±20.3%) and the PRP gels (63.1±25.3%) increased bone formation significantly. No significant difference was observed between sites, where PRP or fibrin has been used as a delivery system for rhBMP-2 (ANOVA). In conclusion, the application of fibrin gels or PRP gels to bone defects is not superior to leaving the defect untreated. Regarding the amount of bone formation, the application of 15 μg rhBMP-2 in bone defects enhances the healing significantly at 4 weeks. In this animal model, commercially available fibrin and autologous PRP gels are equally effective as delivery systems for rhBMP-2. Copyright © Blackwell Munksgaard 2005.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLRen_US
dc.relation.ispartofClinical Oral Implants Researchen_US
dc.subjectBone Graften_US
dc.subjectBone Morphogenetic Proteinsen_US
dc.subjectBone Regenerationen_US
dc.subjectDelivery Systemen_US
dc.subjectFibrinen_US
dc.subjectGrowth Substancesen_US
dc.subjectPlatelet-Rich Plasma (Prp)en_US
dc.titlePlatelet-rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein-2en_US
dc.typeArticleen_US
dc.identifier.emailZwahlen, R:zwahlen@hku.hken_US
dc.identifier.authorityZwahlen, R=rp00055en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1600-0501.2005.01183.xen_US
dc.identifier.scopuseid_2-s2.0-33644679189en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33644679189&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue6en_US
dc.identifier.spage676en_US
dc.identifier.epage682en_US
dc.identifier.isiWOS:000233290200007-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridJung, RE=7201892502en_US
dc.identifier.scopusauthoridSchmoekel, HG=6603126631en_US
dc.identifier.scopusauthoridZwahlen, R=7004217269en_US
dc.identifier.scopusauthoridKokovic, V=14024516700en_US
dc.identifier.scopusauthoridHammerle, CHF=7005331848en_US
dc.identifier.scopusauthoridWeber, FE=7201702808en_US
dc.identifier.citeulike394147-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats